236 related articles for article (PubMed ID: 20599793)
21. The role of the androgen receptor in the development and progression of prostate cancer.
Jenster G
Semin Oncol; 1999 Aug; 26(4):407-21. PubMed ID: 10482183
[TBL] [Abstract][Full Text] [Related]
22. Activation of two mutant androgen receptors from human prostatic carcinoma by adrenal androgens and metabolic derivatives of testosterone.
Culig Z; Stober J; Gast A; Peterziel H; Hobisch A; Radmayr C; Hittmair A; Bartsch G; Cato AC; Klocker H
Cancer Detect Prev; 1996; 20(1):68-75. PubMed ID: 8907206
[TBL] [Abstract][Full Text] [Related]
23. FOXP1 is an androgen-responsive transcription factor that negatively regulates androgen receptor signaling in prostate cancer cells.
Takayama K; Horie-Inoue K; Ikeda K; Urano T; Murakami K; Hayashizaki Y; Ouchi Y; Inoue S
Biochem Biophys Res Commun; 2008 Sep; 374(2):388-93. PubMed ID: 18640093
[TBL] [Abstract][Full Text] [Related]
24. Androgen induction of the androgen receptor coactivator four and a half LIM domain protein-2: evidence for a role for serum response factor in prostate cancer.
Heemers HV; Regan KM; Dehm SM; Tindall DJ
Cancer Res; 2007 Nov; 67(21):10592-9. PubMed ID: 17975004
[TBL] [Abstract][Full Text] [Related]
25. Potent antiandrogen and androgen receptor activities of an Angelica gigas-containing herbal formulation: identification of decursin as a novel and active compound with implications for prevention and treatment of prostate cancer.
Jiang C; Lee HJ; Li GX; Guo J; Malewicz B; Zhao Y; Lee EO; Lee HJ; Lee JH; Kim MS; Kim SH; Lu J
Cancer Res; 2006 Jan; 66(1):453-63. PubMed ID: 16397261
[TBL] [Abstract][Full Text] [Related]
26. TGF-beta signaling and androgen receptor status determine apoptotic cross-talk in human prostate cancer cells.
Zhu ML; Partin JV; Bruckheimer EM; Strup SE; Kyprianou N
Prostate; 2008 Feb; 68(3):287-95. PubMed ID: 18163430
[TBL] [Abstract][Full Text] [Related]
27. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer.
Agoulnik IU; Vaid A; Nakka M; Alvarado M; Bingman WE; Erdem H; Frolov A; Smith CL; Ayala GE; Ittmann MM; Weigel NL
Cancer Res; 2006 Nov; 66(21):10594-602. PubMed ID: 17079484
[TBL] [Abstract][Full Text] [Related]
28. Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells.
Sadar MD; Gleave ME
Cancer Res; 2000 Oct; 60(20):5825-31. PubMed ID: 11059779
[TBL] [Abstract][Full Text] [Related]
29. Transforming growth factor-beta1 induces nuclear to cytoplasmic distribution of androgen receptor and inhibits androgen response in prostate smooth muscle cells.
Gerdes MJ; Dang TD; Larsen M; Rowley DR
Endocrinology; 1998 Aug; 139(8):3569-77. PubMed ID: 9681509
[TBL] [Abstract][Full Text] [Related]
30. Molecular aspects of androgenic signaling and possible targets for therapeutic intervention in prostate cancer.
Culig Z; Santer FR
Steroids; 2013 Sep; 78(9):851-9. PubMed ID: 23643785
[TBL] [Abstract][Full Text] [Related]
31. Androgen receptor as a therapeutic target.
Gao W
Adv Drug Deliv Rev; 2010 Oct; 62(13):1277-84. PubMed ID: 20708648
[TBL] [Abstract][Full Text] [Related]
32. Endocrine disruptors provoke differential modulatory responses on androgen receptor and pregnane and xenobiotic receptor: potential implications in metabolic disorders.
Chaturvedi NK; Kumar S; Negi S; Tyagi RK
Mol Cell Biochem; 2010 Dec; 345(1-2):291-308. PubMed ID: 20830510
[TBL] [Abstract][Full Text] [Related]
33. [Androgen--biosynthesis, receptor and action].
Shiina H; Igawa M
Nihon Rinsho; 1997 Nov; 55(11):2860-4. PubMed ID: 9396277
[TBL] [Abstract][Full Text] [Related]
34. A novel selective androgen receptor modulator (SARM) MK-4541 exerts anti-androgenic activity in the prostate cancer xenograft R-3327G and anabolic activity on skeletal muscle mass & function in castrated mice.
Chisamore MJ; Gentile MA; Dillon GM; Baran M; Gambone C; Riley S; Schmidt A; Flores O; Wilkinson H; Alves SE
J Steroid Biochem Mol Biol; 2016 Oct; 163():88-97. PubMed ID: 27106747
[TBL] [Abstract][Full Text] [Related]
35. Human prostatic cell line PNT1A, a useful tool for studying androgen receptor transcriptional activity and its differential subnuclear localization in the presence of androgens and antiandrogens.
Avancès C; Georget V; Térouanne B; Orio F; Cussenot O; Mottet N; Costa P; Sultan C
Mol Cell Endocrinol; 2001 Nov; 184(1-2):13-24. PubMed ID: 11694337
[TBL] [Abstract][Full Text] [Related]
36. Agonist-mediated docking of androgen receptor onto the mitotic chromatin platform discriminates intrinsic mode of action of prostate cancer drugs.
Kumar S; Chaturvedi NK; Kumar S; Tyagi RK
Biochim Biophys Acta; 2008 Jan; 1783(1):59-73. PubMed ID: 18070607
[TBL] [Abstract][Full Text] [Related]
37. Sirtuin 1 is required for antagonist-induced transcriptional repression of androgen-responsive genes by the androgen receptor.
Dai Y; Ngo D; Forman LW; Qin DC; Jacob J; Faller DV
Mol Endocrinol; 2007 Aug; 21(8):1807-21. PubMed ID: 17505061
[TBL] [Abstract][Full Text] [Related]
38. The transcriptional programme of the androgen receptor (AR) in prostate cancer.
Lamb AD; Massie CE; Neal DE
BJU Int; 2014 Mar; 113(3):358-66. PubMed ID: 24053777
[TBL] [Abstract][Full Text] [Related]
39. Structures of androgen receptor bound with ligands: advancing understanding of biological functions and drug discovery.
Sakkiah S; Ng HW; Tong W; Hong H
Expert Opin Ther Targets; 2016 Oct; 20(10):1267-82. PubMed ID: 27195510
[TBL] [Abstract][Full Text] [Related]
40. Pregnane X receptor as a therapeutic target to inhibit androgen activity.
Zhang B; Cheng Q; Ou Z; Lee JH; Xu M; Kochhar U; Ren S; Huang M; Pflug BR; Xie W
Endocrinology; 2010 Dec; 151(12):5721-9. PubMed ID: 20962047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
